Loading…
BOOTS NICASSIST is a brand name for Nicotine. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Nicorette Nasal Spray relieves and/or prevents craving and nicotine withdrawal symptoms in nicotine dependence, such as those arising from the use of tobacco or electronic cigarettes. It is indicated to aid quitting or reduction prior to quitting, to assist those who are unwilling or unable to use such products and as…
Verbatim from this product's MHRA label. Tap a section to expand.
The patient should make every effort to stop smoking/vaping completely during treatment with Nicorette Nasal Spray. Behavioural therapy, advice and support will normally improve the success rate. This product must only be used with other NRT products under the advice of a healthcare professional.
This product is sprayed into the nostril when the unit is activated. If the eyes are sprayed, rinse thoroughly with water. Directions for use 1) Remove the protective cap. 2) Prime Nicorette Nasal Spray by placing the nozzle between first and second finger with the thumb on the bottom of the bottle.
Press several times firmly and quickly until a fine spray appears (up to 7-8 strokes).
Important:
Point the spray safely away when priming it. Do not prime it near children or pets. 3) Insert the spray tip into one nostril, pointing the top towards the back of the nose. Press firmly and quickly. Give a spray into the other nostril.
4) Put on the protective cap Smoking/Vaping Cessation Adults (over 18 years of age) 1. The frequency of use depends on the previous smoking/vaping habit of the individual and the level of their nicotine dependence. 2. On commencing treatment the patient uses the spray to treat craving as required, subject to a limit of one spray to each nostril twice an hour.
3. A 50 μl dose of solution is sprayed into the nostril when the unit is activated. This is described as a “spray” and dosage is described using this term. 5 mg of nicotine, about half of which is absorbed. 4. The daily limit of use is 32 mg of nicotine (64 sprays) which is the equivalent of two sprays to each nostril every hour for 16 hours.
5. The method of use of the spray should be according to the instructions. 6. The 3 month course should take the following pattern: a. For 8 weeks the patient uses the spray as required, subject to the maxima described above, to relieve craving.
b. After this period the patient reduces usage until after 4 more weeks treatment has ended. It is suggested that after 2 weeks into this period usage will have been reduced by a half and usage be zero by the last day. Spraying into a single nostril during this period may be helpful in achieving this.
c. Treatment should be limited to three months. The patient should understand the aim of decreasing the use of the spray to make a final break with nicotine at the end of the course, and also accept that for the first few days of the course nasal irritation may be unpleasant.
Effects of Smoking Cessation Some symptoms may be related to nicotine withdrawal associated with stopping smoking. These can include irritability/aggression, dysphoria/depressed mood, anxiety, restlessness, poor concentration, increased appetite/weight gain, urges to smoke (cravings), night-time awakenings/sleep disturbance, decreased heart rate, dizziness, presyncopal symptoms, cough, constipation, gingival bleeding or nasopharyngitis.
Increased frequency of aphthous ulcer may occur after abstinence from smoking. The causality is unclear. Effects of Vaping Cessation The nicotine withdrawal effects of vaping cessation have not been established; however it is anticipated that many of the effects relating to nicotine withdrawal will be the same as those with tobacco smoking cessation.
Adverse Drug Reactions This product may cause adverse reactions similar to those associated with nicotine given by other means, including smoking and vaping, and these are mainly dose-dependent. At recommended doses this product has not been found to cause any serious adverse effects.
Excessive use of this product by those who have not been in the habit of inhaling tobacco smoke or vaping could possibly lead to nausea, faintness or headaches. During the first 2 days of treatment, nasal irritation as sneezing, running nose, watering eyes, cough was reported by nearly all (94%) of the patients.
Both the frequency and severity declined with continued use. Allergic reactions (including symptoms of anaphylaxis) can occur during the use of this product. The adverse reactions observed in patients treated with nicotine nasal spray formulations during clinical trials and post-marketing experience are listed below by System Organ Class (SOC).
Frequencies are defined in accordance with current guidance as: very common (≥1/10); common (≥1/100, <1/10); uncommon (≥1/1 000, < 1/100); rare (≥1/10 000, <1/1 000); very rare (<1/10 000), not known (cannot be estimated from the available data).
Any risks that may be associated with NRT are substantially outweighed by the well-established dangers of continued smoking. The risks of continued vaping are not yet established. A risk-benefit assessment should be made by an appropriate healthcare professional for patients with the following conditions: Underlying cardiovascular disease: In stable cardiovascular disease this product presents a lesser hazard than continuing to smoke.
However dependent smokers currently hospitalised as a result of myocardial infarction, unstable or worsening angina including Prinzmetal angina, severe dysrhythmia or CVA and who are considered to be haemodynamically unstable and/or who have uncontrolled hypertension should be encouraged to stop smoking with non-pharmacological interventions.
If this fails, this product may be considered, but as data on safety in this patient group are limited, initiation should only be under medical supervision. The risks of continued vaping are not yet established.
Diabetes mellitus:
Patients with diabetes mellitus should be advised to monitor their blood sugar levels more closely than usual when quitting and NRT is initiated as reductions in nicotine induced catecholamines release can affect carbohydrate metabolism.
GI disease:
Nicotine may exacerbate symptoms in patients suffering from oesophagitis, gastritis or peptic ulcers and NRT preparations should be used with caution in these conditions. Ulcerative stomatitis has been reported.
Renal or hepatic impairment:
Nicorette Nasal Spray should be used with caution in patients with moderate to severe hepatic impairment and/or severe renal impairment as the clearance of nicotine or its metabolites may be decreased with the potential for increased adverse effects.
Hypersensitivity to any component of the nasal spray. Nicorette Nasal Spray is contraindicated in children under the age of 12 years.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Nicotine in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Adults who use NRT beyond 9 months are recommended to seek additional help and advice from a healthcare professional. Adolescents (12 to 18 years) The dose and method of use are as for adults however as data are limited in this age group, the recommended treatment duration is 12 weeks.
If longer treatment is required, advice from a healthcare professional should be sought. Smoking/Vaping Reduction Adults (over 18 years of age) Use this product between smoking/vaping episodes to manage the urge to smoke/vape, to prolong smoke/vape-free intervals and with the intention to reduce smoking/vaping as much as possible.
If a reduction in number of cigarettes/e-cigarettes per day has not been achieved after 6 weeks, professional advice should be sought. A quit attempt should be made as soon as the patient feels ready, but not later than 6 months after start of treatment.
If a quit attempt cannot be made within 9 months after starting treatment, professional advice should be sought. When making a quit attempt the smoking/vaping cessation instructions above can be followed. Adolescents (12 to 18 years) Where adolescents are motivated to stop smoking/vaping abruptly, smoking/vaping cessation should be recommended.
However, smoking/vaping reduction can be considered where adolescents are not ready or able to stop smoking/vaping abruptly. As data are limited in this age group, and the recommended duration of NRT is 12 weeks, adolescents should consult a healthcare professional before starting the “smoking/vaping reduction prior to stopping” regimen.
Use this product between smoking/vaping episodes, as needed to manage the urge to smoke/vape, to prolong smoke/vape-free intervals and to reduce their use as much as possible. If a reduction in number of cigarettes/e-cigarettes per day has not been achieved after 6 weeks, professional advice should be sought.
A quit attempt should be made as soon as the patient feels ready, but not later than 6 months after start of treatment. If a quit attempt cannot be made within 9 months after starting treatment, professional advice should be sought.
When making a quit attempt the smoking/vaping cessation instructions for adolescents (12 to 18 years) given above can be followed.
System Organ Class Reported Adverse Event Incidence Immune System Disorders Hypersensitivityac# Anaphylactic reactionb Uncommon Not known Psychiatric Disorders Abnormal dreams* Uncommon Nervous System Disorders Headachea Dizziness Paraesthesiaa Seizures Common Common Common Not known Eye Disorders Lacrimation increased Not known Cardiac Disorders Palpitationsa Atrial fibrillation Tachycardiaa Common Very rare Not known Vascular Disorders Flushinga Hypertensiona Uncommon Uncommon Respiratory, Thoracic and Mediastinal Disorders Rhinorrhoea Cough** Throat irritation** Dyspnoeaa Epistaxis Nasal discomfort Oropharyngeal discomfort and pain Sneezing Very common Common Common Common Common Not known Not known Not known Gastrointestinal Disorders Nauseaa Vomitinga Gastrointestinal discomforta Common Common Not known Skin and Subcutaneous Tissue Disorders Hyperhidrosisa Pruritusa Rasha Angioedemaa Erythemaa Common Common Common Not known Not known Urticariaa Not known General Disorders and Administration Site Conditions Chest discomfort and paina Fatigueac Malaisea Astheniaa Common Uncommon Uncommon Not known a Systemic effects; b Reported the same or less frequently than placebo.
c Although the frequency is <1% the PT occurred at a frequency ≥1% in another formulation in which the PT was identified as a systemic ADR *Identified only for formulations applied during the night **Higher frequency observed in clinical studies with inhaler formulation.
# Although the frequency in the active group is less than that of the placebo group, the frequency in the specific formulation in which the PT was identified as a systemic ADR was greater in the active group than the placebo group.
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Seizures:
Potential risks and benefits of nicotine should be carefully evaluated before use in subjects with a history of epilepsy as cases of convulsions have been reported in association with nicotine.
Danger in children:
Doses of nicotine tolerated by adult and adolescent smokers or vapers can produce severe toxicity in children that may be fatal. Products containing nicotine should not be left where they may be misused, handled or ingested by children.
Phaeochromocytoma and uncontrolled hyperthyroidism:
As nicotine causes release of catecholamines, this product should be used with caution in patients with uncontrolled hyperthyroidism or phaeochromocytoma.
Transferred dependence:
Transferred dependence is rare and is both less harmful and easier to break than smoking dependence.
Stopping smoking:
Polycyclic aromatic hydrocarbons in tobacco smoke induce the metabolism of drugs metabolised by CYP 1A2 (and possibly by CYP 1A1). When a smoker stops smoking, this may result in slower metabolism and a consequent rise in blood levels of such drugs.
g. theophylline, clozapine and ropinirole.
Bronchial asthma:
A few cases of exacerbation of bronchospasm in patients with bronchial asthma have been reported. Use of the spray in patients with hyperreactive airways is not recommended.
Excipients:
This product contains methyl- and propyl- hydroxybenzoates (E217 and E218); which may cause allergic reactions (possibly delayed) and exceptionally, bronchospasm. A clinical study confirms the safe use of this product, by smokers with chronic rhinitis and sinusitis.
Care should be taken not to spray the eyes whilst administering the spray.